Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-23T04:48:13.652Z Has data issue: false hasContentIssue false
  • English
  • Français

Small cell carcinoma of the head and neck: report of three cases

Published online by Cambridge University Press:  08 August 2013

H Matsuyama ,
K Yamazaki ,
M Tomita  and
S Takahashi
H Matsuyama*
Affiliation:
Department of Otolaryngology, Faculty of Medicine, Niigata University, Japan
K Yamazaki
Affiliation:
Department of Otolaryngology, Faculty of Medicine, Niigata University, Japan
M Tomita
Affiliation:
Department of Otolaryngology, Faculty of Medicine, Niigata University, Japan
S Takahashi
Affiliation:
Department of Otolaryngology, Faculty of Medicine, Niigata University, Japan
*
Address for correspondence: Dr Hiroshi Matsuyama, Department of Otolaryngology, Niigata University, Faculty of Medicine, 1-757 Asahimachi-dori, Chuo-ku, Niigata-shi 951-8510, Japan Fax: +81 25 227 0786 E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Small cell carcinoma of the head and neck is rare and has unique histopathological characteristics that make it difficult to diagnose and treat. In this report, the Japanese Lung Cancer Treatment Guidelines were adapted to treat three patients with small cell carcinoma of the head and neck, and outcomes evaluated.

Methods:

There was one case each of stage I small cell carcinoma of the nasal cavity, stage IV-B small cell carcinoma of the ethmoid sinus, and stage IV-A small cell carcinoma of the submandibular gland. All patients underwent chemoradiotherapy and achieved a partial response.

Results:

Only case one underwent surgery after chemoradiotherapy; 31 months after treatment, this patient had suffered no recurrence. Case two died three months after treatment due to bone marrow metastasis. Case three had experienced no progression after 12 months of follow up.

Conclusion:

In this small patient series, short-term results were equivalent to or better than usual treatment outcomes for small cell carcinoma of the lung.

Keywords

Head And Neck NeoplasmsCarcinoma, Small CellOtolaryngologyChemoradiotherapyGuidelines
Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 127 , Issue 9 , September 2013 , pp. 942 - 946
Copyright
Copyright © JLO (1984) Limited 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Pignon, JP, Arriagada, R, Ihde, DC, Johnson, DH, Perry, MC, Souhami, RL et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618–24CrossRefGoogle ScholarPubMed
2Warde, P, Payne, D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890–5CrossRefGoogle ScholarPubMed
3Noda, K, Nishiwaki, Y, Kawahara, M, Negoro, S, Sugiura, T, Yokoyama, A et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85–91CrossRefGoogle ScholarPubMed
4Jeremic, B, Shibamoto, Y, Acimovic, L, Milisavljevic, S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997;15:893–900CrossRefGoogle Scholar
5Takada, M, Fukuoka, M, Kawahara, M, Sugiura, T, Yokoyama, A, Yokota, S et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054–60CrossRefGoogle Scholar
6Choi, NC, Herndon, JE 2nd, Rosenman, J, Carey, EW, Chung, CT, Bernard, S et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3528–36CrossRefGoogle ScholarPubMed
7Macbeth, FR, Wheldon, TE, Girling, DJ, Stephens, RJ, Machin, D, Bleehen, NM et al. Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung-cancer. The Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 1996;8:176–81CrossRefGoogle ScholarPubMed
8Ettinger, DS, Finkelstein, DM, Abeloff, MD, Ruckdeschel, JC, Aisner, SC, Eggleston, JC. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990;8:230–40CrossRefGoogle ScholarPubMed
9Sculier, JP, Paesmans, M, Bureau, G, Giner, V, Lecomte, J, Michel, J et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1996;14:2337–44CrossRefGoogle ScholarPubMed
10Ebi, N, Kubota, K, Nishiwaki, Y, Hojo, F, Matsumoto, T, Kakinuma, R et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 1997;27:166–9CrossRefGoogle ScholarPubMed
11Eisenhauer, EA, Therasse, P, Bogaerts, J, Schwartz, LH, Sargent, D, Ford, R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47CrossRefGoogle ScholarPubMed
12Calvert, AH, Newell, DR, Gumbrell, LA, O'Reilly, S, Burnell, M, Boxall, FE et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;11:1748–56CrossRefGoogle Scholar
13Galanis, E, Frytak, S, Lloyd, RV. Extrapulmonary small cell carcinoma. Cancer 1997;79:1729–363.0.CO;2-#>CrossRefGoogle ScholarPubMed
14Kim, KO, Lee, HY, Chun, SH, Shin, SJ, Kim, MK, Lee, KH et al. Clinical overview of extrapulmonary small cell carcinoma. J Korean Med Sci 2006;21:833–7CrossRefGoogle ScholarPubMed
15Gregory, R. Small cell carcinoma of the head and neck: a review. Semin Oncol 2007;34:3–14Google Scholar
16Ferlito, A, Barnes, L, Rinaldo, A, Gneep, DR, Milroy, CM. A review of neuroendocrine neoplasms of the larynx: update on diagnosis and treatment. J Laryngol Otol 1998;112:827–34CrossRefGoogle ScholarPubMed
17Rosenthal, DI, Barker, JL, EL-Naggar, AK. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer 2004;101:2567–73CrossRefGoogle ScholarPubMed
18Barnes, L, Eveson, JW, Reichert, P, Sidransky, D. Pathology and Genetics of Head and Neck Tumors (World Health Organization Classification of Tumors). Lyon: IARC Press, 2005;135–9Google Scholar
19Mills, SE. Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas. Mod Pathol 2002;15:264–78CrossRefGoogle ScholarPubMed
20Micke, P, Faldum, A, Metz, T, Beeh, KM, Bittinger, F, Hengstler, JG et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? Lung Cancer 2002;37:271–6CrossRefGoogle Scholar
21Lee, CH, Lin, HC. Descriptive study of prognostic factors influencing survival of patients with primary tracheal tumors. Chang Gung Med J 1995;18:224–30Google ScholarPubMed
22Muller, AC, Gani, C, Weinmann, M, Mayer, F, Sipos, B, Bamberg, M et al. Limited disease of extra-pulmonary small cell carcinoma. Impact of local treatment and nodal status, role of cranial irradiation. Strahlenther Onkol 2012;188:269–73CrossRefGoogle ScholarPubMed
23Lee, SS, Lee, JL, Ryu, MH, Chang, HM, Kim, TW, Kim, WK et al. Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol 2007;46:846–51Google ScholarPubMed